Carprieve is used to reduce pain and inflammation. It is effective for chronic conditions such as degenerative joint disease (osteoarthritis) as well as injuries to the musculo-skeletal system. It can also be used as an aid in post-operative recovery. In common with other NSAIDs, Carprieve should not be used in dehydrated or debilitated dogs, and medication should be paused or terminated if vomiting or diarrhoea occur.
Carprieve is available in unflavoured (small, white) tablets, or in larger flavoured and palatable, chewable tablets
N.B. - Carprieve was previously called Norocarp.
Contra-indications, warnings, etc
The use of Norocarp Tablets is contraindicated in the cat, and the inadvertent administration of oral carprofen tablets may induce life-threatening conditions in this species.
Do not exceed the stated dose.
Do not administer NSAIDs concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
In the absence of any specific studies in pregnant target bitches, such use is not indicated.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
All prices include VAT where applicable.
Below are some recent questions we've received regarding Carprieve, including answers from our team.Ask Your Own Question